$9.72
9.75% yesterday
NYSE, Apr 03, 10:05 pm CET
ISIN
US28414H1032
Symbol
ELAN

Elanco Animal Health, Inc. Stock price

$9.72
-1.59 14.06% 1M
-4.78 32.97% 6M
-2.39 19.74% YTD
-5.71 37.01% 1Y
-16.44 62.84% 3Y
-10.47 51.86% 5Y
-26.28 73.00% 10Y
NYSE, Closing price Thu, Apr 03 2025
-1.05 9.75%
ISIN
US28414H1032
Symbol
ELAN

Key metrics

Market capitalization $4.81b
Enterprise Value $8.78b
P/E (TTM) P/E ratio 14.33
EV/FCF (TTM) EV/FCF 22.29
EV/Sales (TTM) EV/Sales 1.98
P/S ratio (TTM) P/S ratio 1.08
P/B ratio (TTM) P/B ratio 0.79
Revenue growth (TTM) Revenue growth 0.50%
Revenue (TTM) Revenue $4.44b
EBIT (operating result TTM) EBIT $251.00m
Free Cash Flow (TTM) Free Cash Flow $394.00m
Cash position $468.00m
EPS (TTM) EPS $0.68
P/E forward negative
P/S forward 1.07
EV/Sales forward 1.96
Short interest 4.75%
Show more

Is Elanco Animal Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Elanco Animal Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Elanco Animal Health, Inc. forecast:

9x Buy
60%
6x Hold
40%

Analyst Opinions

15 Analysts have issued a Elanco Animal Health, Inc. forecast:

Buy
60%
Hold
40%

Financial data from Elanco Animal Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,439 4,439
0% 0%
100%
- Direct Costs 2,530 2,530
2% 2%
57%
1,909 1,909
1% 1%
43%
- Selling and Administrative Expenses 652 652
10% 10%
15%
- Research and Development Expense 344 344
5% 5%
8%
913 913
10% 10%
21%
- Depreciation and Amortization 662 662
5% 5%
15%
EBIT (Operating Income) EBIT 251 251
23% 23%
6%
Net Profit 338 338
127% 127%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Elanco Animal Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elanco Animal Health, Inc. Stock News

Neutral
PRNewsWire
18 days ago
GREENFIELD, Ind. , March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders: John P.
Neutral
Seeking Alpha
about one month ago
Elanco Animal Health Incorporated (NYSE:ELAN ) Q4 2024 Earnings Conference Call February 25, 2024 8:00 AM ET Company Participants Tiffany Kanaga - Head of IR Jeffrey Simmons - President & CEO Todd Young - EVP & CFO Conference Call Participants Jonathan Block - Stifel Michael Ryskin - Bank of America Daniel Clark - Leerink Partners Andrea Alfonso - UBS Erin Wright - Morgan Stanley Balaji Prasad ...
Neutral
PRNewsWire
about one month ago
Fourth Quarter 2024 Financial Results: Revenue of $1,020 million, decreased 1% on a reported basis and increased 4% on an organic constant currency basis Reported Net Loss of $8 million, Adjusted Net Income of $72 million Adjusted EBITDA of $177 million, or 17.4% of Revenue, including an approximate $7 million foreign exchange (FX) headwind vs. late October rates Reported EPS of $(0.02), Adjust...
More Elanco Animal Health, Inc. News

Company Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Head office United States
CEO Jeffrey Simmons
Employees 9,450
Founded 1954
Website www.elanco.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today